newsfilter
← Latest News
GlobeNewswire·

Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines

  • argenx has entered a definitive agreement to acquire Unnatural Products (UNP) for an upfront payment of $550 million plus contingent value rights tied to development & regulatory milestones, totaling up to approximately $1.15 billion.
  • The acquisition concludes a two-year multi-target research collaboration & will see UNP's team & macrocycle platform operate as argenx's dedicated macrocyclic peptide discovery hub in Santa Cruz.
  • Closing of the transaction is expected by year-end 2026, subject to customary closing conditions.
  • UNP's AI-guided discovery platform pairs massively parallel synthesis with direct-to-biology screening to engineer drug-like macrocycles for previously undruggable intracellular targets.
  • Founded in 2016 by Cameron Pye & Joshua Schwochert, UNP has secured partnerships with Novartis, Merck, & BridgeBio while employing over 50 people in Santa Cruz.
  • argenx CEO Karen Massey stated the deal adds macrocyclic peptide capabilities to complement its antibody engineering, aiming to create new possibilities for oral & long-acting medicines.
Company
Unnatural Products, Inc.
Keywords
Unnatural Products, Inc.